{"id":"jns020qd","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, JNS020QD reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"JNS020QD is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:41.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01493245","phase":"PHASE3","title":"A Study of JNS020QD in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-10","conditions":"Chronic Pain","enrollment":77},{"nctId":"NCT01008618","phase":"PHASE3","title":"A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2009-01","conditions":"Chronic Pain, Osteoarthritis, Low Back Pain","enrollment":218},{"nctId":"NCT01008553","phase":"PHASE3","title":"A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-12","conditions":"Postherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS), Postoperative Pain","enrollment":258},{"nctId":"NCT00788372","phase":"PHASE3","title":"An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-11","conditions":"Chronic Pain","enrollment":142},{"nctId":"NCT00644787","phase":"PHASE2, PHASE3","title":"A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2007-12","conditions":"Pain, Cancer","enrollment":156},{"nctId":"NCT00641667","phase":"PHASE3","title":"An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-01","conditions":"Pain, Cancer","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JNS020QD","genericName":"JNS020QD","companyName":"Janssen Pharmaceutical K.K.","companyId":"janssen-pharmaceutical-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JNS020QD is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}